



REF: - SAROJA/NSE/2024

13.11.2024

To,

The Manager,
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir,

Sub.: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and Un-Audited Standalone Financial Results for the Half year ended 30th September 2024 under regulation 33(3) of SEBI (LODR) Regulation 2015 alongwith Limited Review Report.

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. 13th November, 2024 have inter-alia considered, noted and approved the following:

- 1) Unaudited Standalone Financial Results for the Half Year Ended 30th September, 2024 alongwith Independent Auditor's Review Report issued by the Statutory Auditors(As attached herewith).

The Board Meeting commenced today at 11:30 A.M. and concluded at 07.00 P.M.

The above intimation is given to you for your record. Kindly take note of the same.

Thanking You,
Yours faithfully,

For Saroja Pharma Industries India Limited

Manish Dasharath Kamble
Whole - Time Director
DIN : 08330224



*Pravin Chandak
Associates*

Chartered Accountants

Independent Auditor's Review Report on Unaudited Financial Results for the half year ended 30 September 2024 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

Saroja Pharma Industries India Limited

(formerly known as **Saroja Pharma Industries India Private Limited**)

1. We have reviewed the accompanying Statement of Unaudited Financial Results ("Statement") of **Saroja Pharma Industries India Limited** (formerly known as **Saroja Pharma Industries India Private Limited**) for the half year ended 30 September 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express an opinion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements.



403, 4th Floor & 702/703, 7th Floor,
New Swapnalok CHS Ltd.,
Natakwala Lane, Borivali (West),
Mumbai - 400 092. Tel : 2801 6119
Email : info@pravinca.com
Website : www.pravinca.com

4. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 s amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed he information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Pravin Chandak & Associates

Chartered Accountants

ICAI Firm Registration Number: 116627W



Partner

Membership No: 049391

UDIN: **24049391BKBNMV8490**

Place: Mumbai

Date: 12/11/2024




SAROJA PHARMA INDUSTRIES INDIA LIMITED.

CIN : U24110MH2019PLC319508

REGD. OFFICE 305, KAILASH TOWER, SHIV SHRISTI COMPLEX, GOREGOAN LINK ROAD, MULUND WEST MUMBAI-400080

STATEMENT OF ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

Particulars		(In Lakhs)	
		As at 30.09.2024	As at 31.03.2024
A	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share Capital	402.05	402.05
	(b) Securities Premium	0.00	0.00
	(c) Reseve & Surplus	1095.64	1062.10
	Sub-Total - Equity	1497.69	1464.15
	Liabilities		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings (Secured/Unsecured Loans)	201.53	262.06
	(ii) Trade Payables	0.00	0.00
	(iii) Other Financial Liabilities (other than those specified in them (b) to be specified)	0.00	0.00
	(b) Provisions	0.00	0.00
	(c) Deferred Tax Liabilities (Net)	0.85	0.85
	(d) Other Non-Current Liabilities	0.00	0.00
	Sub-Total - Non current Liabilities	202.38	262.91
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings (Bank Loan/ Bank of Baroda)	673.16	311.44
	(ii) Trade payables	530.05	560.89
	I. total outstanding dues of micro enterprises and small enterprises		
	II. Total outstanding dues of creditors other than micro enterprises and smalll enterprises		
	(iii) Other Financial Liabilities (Current Maturities of long term debt)	0.00	0.00
	(b) Other Current Liabilities	-23.54	56.47
	(c) Provisions	9.76	0.38
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Sub-Total- Current Liabilites	1189.43	929.18
	TOTAL-EQUITY AND LIABILITIES	2889.50	2656.24
B	ASSETS		
1	Non- current Assets		
	(a) Property, Plant and Equipment	246.75	251.20
	(b) Capital work-in-progress	680.76	612.66
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other intagible Assets under Development	0.00	0.00
	(f) Intangible Assets under Development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(e) Financial Assets	0.00	0.00
	(i) Investments	24.63	19.92
	(ii) Trade Receivables	0.00	0.00
	(iii) Loans (Deposit ass)	3.58	12.69
	(d) Deferred Tax Assets (net)	0.00	0.00
	(e) Other Non-current Assets	0.00	0.00
	Sub-total - Non - current Assets	955.72	896.47



2 Current Assets		
(a) Inventories (Closing Stock)	33.32	39.77
(b) Financial Assets		
(i) Investment	0.00	0.00
(ii) Trade Receivable	1762.17	1624.02
(iii) Cash and Cash Equivalents	133.73	32.18
(iv) Bank Balances other than (iii) above	0.00	0.00
(v) Loans (Loan & Advance)	3.50	4.50
(vi) Others (to be specified)	0.00	0.00
(c) Current Tax Assets (Net)	0.00	0.00
(d) Other Current Assets	1.06	59.30
Sub-Total - Current Assets	1933.78	1759.77
TOTAL - ASSETS	2889.50	2656.24

Significant Accounting Policies & Notes on Accounts

For Pravin Chandak & Associates

Chartered Accountant

Firm Regn No: 116627W

Pravin Chandak

Partner

Membership No.:049391

UDIN: 24049391BKBNMY8490

Place: Mumbai

Date: 12/11/2024

For & on behalf of the Board of Directors

SAROJA PHARMA INDUSTRIES INDIA LTD

(FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)

Biju G Nair

Managing Director

DIN: 08330223

Manish D Kamble

Wholetime Director

DIN: 08330224



SAROJA PHARMA INDUSTRIES INDIA LIMITED.
CIN : U24110MH2019PLC319508

REGD. OFFICE 305, KAILASH TOWER, SHIV SHRISTI COMPLEX, GOREGOAN LINK ROAD, MULUND WEST MUMBAI-400080
STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE SIX MONTH ENDED ON 30th SEPTEMBER, 2024

(Rs. In Lakhs Except EPS)

Sr No.	Particulars	6 Months Ended			Year ended	
		30.09.2024	31.03.2024	30.09.2023	31.03.2024	31.03.2023
		Unaudited	Audited	Unaudited	Audited	Audited
1	Income form Operations					
	Net Sales / Income From Operations	1,872.40	1,955.06	2,111.87	4,066.93	5,019.32
	Other Oprating income	7.26	-19.29	38.61	19.32	15.77
	Total Income from Oprations (Net)	1,879.66	1,935.77	2,150.48	4,086.25	5,035.09
2	Expenditure					
	Cost of material consumed	1,635.83	1,709.48	1,507.80	3,217.28	4,869.52
	Purchase of stock in trade	0.00	-	0.00	0.00	0.00
	Changes in Inventories of finished goods, work-in-progress and stock in trade	6.46	-13.57	360.38	346.81	-339.93
	Employees cost	59.07	74.09	72.19	146.28	136.76
	Depreciation	5.32	5.89	3.56	9.45	6.66
	Finance Cost	68.94	61.82	82.75	144.57	131.89
	Power and Fuel	0.00	0.00	0.00	0.00	0.00
	Other Expenses	57.57	46.87	54.28	101.15	81.03
	Total Expenses	1,833.19	1,884.58	2,080.96	3,965.54	4,885.93
4	Profit from Oprations before Exceptional Tax	46.47	51.19	69.52	120.71	149.15
5	Exceptional Items	0.00	0.00	0.00	0.00	0.00
6	Profit before Tax	46.47	51.19	69.52	120.71	149.15
	Current Tax	12.93	13.95	19.34	33.29	42.17
	Deferred Tax	0.00	-0.41	0.00	-0.41	0.92
7	Total Tax Expenses	0.00	0.00	0.00	0.00	0.00
8	Net Profit for the Period From Countinuing Oprations	33.54	37.65	50.18	87.83	106.06
9	Details of Equity Shares					
	Paid up Equity Share Capital					
	Face Value of Equity Share (in Rs.)	10.00	10.00	10.00	10.00	10.00
	Reserves					
10	Earning Per Share					
	Basic Earing Per Share	0.83	0.81	1.68	2.49	3.61
	Dlluted Earing per Share	0.83	0.81	1.68	2.49	3.61

Notes:

- The above Unaudited Financial Statement has been reviewed by the Audit Committee and approved by the Board of the Directors at its meeting held on 13 November, 2024
- These Unaudited financial results have been prepared in accordance With the the Accounting Standard prescribed under section 133 of the Companies Act, 2013
- Relating to segment wise reporting is not applicable as the company oprates in only One Primary sergment i.e pharmaceutical Trading
- The figure pertaining to previous periods have been regrouped, re-classified and restated wherever necessary
- The Company has utilised proceeds from IPO as per the object clause of the prospectus dated 25/08/2023 as detailed below:

Sr	Object Of the Issue	Amount Alloted Fot Project	Amount utilized till 30 Sept 2024	Amount unutilizedtill 30 Sept 2024
1	To Set - up a Manufacturing Unit	704.88	399.98	304.90
2	To Repay the Unsecured Loan of the Company	175.00	175.00	0.00
3	Public Issue Expenses.	31.35	30.97	0.38
		911.23	605.95	305.28

6. Balance and utilise fund of 305.28 received pursue to IPO temporary parking CC account of the company bring down the utifise limit and save interest cost during the Audit period. Additionally, to further reduce the cost of capital, the company temporarily utilized these unutilized funds for working capital needs. The funds were subsequently restored to the CC account by the half year-end, as reported.

Significant Accounting Policies & Notes on Accounts

For Pravin Chandak & Associates
Chartered Accountant
Firm Regn No: 116627W

Pravin Chandak
Partner

Membership No.:049391

UDIN: 210493910KBA1MCH90

Place: Mumbai

Date: 12/11/2024

For & on behalf of the Board of Directors
SAROJA PHARMA INDUSTRIES INDIA LTD
(FORMERLY KNOWN AS SAROJA PHARMA
INDUSTRIES INDIA PVT LTD)

Biju G Nair
Managing Director

Manish D Kamble
Wholtime Director

DIN: 08330223

DIN: 08330224



SAROJA PHARMA INDUSTRIES INDIA LIMITED.

CIN : U24110MH2019PLC319508

REGD. OFFICE 305, KAILASH TOWER, SHIV SHRISTI COMPLEX, GOREGOAN LINK ROAD, MULUND WEST MUMBAI-400080

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER. 2024

Particulars	(In Lakhs)	
	01-04-2024 TO 30-09-2024	01-04-2023 TO 30-03-2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	46.47	120.71
Adjustment For :		
Depreciation of property, plant & equipment	5.32	9.45
Finance cost	68.94	144.57
Interest Income classified as Investing Cash Flows		-2.42
Other Comprehensive Expenses		
(Profit) / Loss on sale of property, plant & equipment		
Operating Profit before working capital changes	120.73	272.31
Adjustment For :		
(a) (Increase)/ Decrease in Inventories	6.45	346.81
(b) (Increase)/ Decrease in Trade Receivables	-138.15	-513.23
(h) (Increase)/ Decrease in Current Assets	58.74	17.41
(c) (Increase)/ Decrease in Non-Current Financial Assets		
(d) Increase/ (Decrease) in Short Term Loans and advance		-0.07
(e) Increase/ (Decrease) in Long Term Borrowings		
(f) Increase / (Decrease) in Short Term Borrowings		0
(g) Increase/ (Decrease) in Other Current Liabilities	-80.01	54.74
(h) Increase/ (Decrease) in Short Term Provisions	9.38	-16.80
(i) Increase/ (Decrease) in Trade Payable	-30.84	-25.41
CASH GENERATED FROM OPERATIONS	-54.20	135.76
Less: (a) Income Tax Paid	-12.93	-33.29
NET CASH INFLOW FROM OPERATING ACTIVITIES (A)	-67.13	102.47
B. CASH FLOW FROM INVESTING ACTIVITIES		
(a) Purchase of Fixed Assets/ Addition to WIP	-68.97	-472.91
(b) Investment	-4.71	-5.73
(c) Interest Income		2.42
NET CASH INFLOW/ (OUTFLOW) FROM INVESTING ACTIVITIES (B)	-73.68	-476.22
C. CASH FLOW FROM FINANCING ACTIVITIES		
(a) Proceeds/ (Repayment) from Borrowings		
(b) Subsidy Received		
(c) Long/Short term Borrowing	301.19	-445.37
(d) Proceeds from Issue of Share Capital		867.66
(e) Interest Paid		0
(f) Long/Short term loans and advances/deposit	10.11	91.8
(g) Finance Cost	-68.94	-144.57
NET CASH INFLOW/(OUTFLOW) IN FINANCING ACTIVITIES (C)	242.36	369.52
NET INCREASE IN CASH & CASH EQUIPMENTS (A+B+C)	101.55	-4.23
OPENING BALANCE - CASH & CASH EQUIPMENT	32.18	36.41
CLOSING BALANCE - CASH & CASH EQUIVALENT	133.73	32.18

SAROJA PHARMA INDUSTRIES INDIA LIMITED.

Significant Accounting Policies & Notes on Accounts

For Pravin Chandak & Associates

Chartered Accountant

Firm Regn No: 116627W

Pravin Chandak

Partner

Membership No.:049391

UDIN:24049391BKBNMY8490

Place: Mumbai

Date: 12/11/2024

For & on behalf of the Board of Directors

SAROJA PHARMA INDUSTRIES INDIA LTD

(FORMERLY KNOWN AS SAROJA PHARMA

INDUSTRIES INDIA PVT LTD)

Biju G Nair

Managing Director

DIN: 08330223

Manish D Kamble

Wholetime Director

DIN: 08330224



SAROJA PHARMA INDUSTRIES INDIA LTD

CIN: U24110MH2019PLC319508

NOTE 25- BASIC AND DILUTED EARNINGS PER SHARE

Particulars		30.09.2024	31.03.2024	30.09.2023	2022-23
Profit after Tax	Rs.	33,54,000.0	37,65,000.0	50,18,000.0	1,06,06,148.00
Present Number of equity shares of Rs. 10/- each	Nos.	40,20,486.0	29,35,686.0	2,10,000.0	29,35,686.00
Weighted average number of Equity	Nos.	40,20,486.0	2,11,343.8	2,10,000.0	2,25,822.00
Weighted average number of Equity shares Shares including bonus	Nos.	40,20,486.00	29,21,207.79	29,19,864.00	29,35,686.00
Basic earnings per share	Rs.	0.83	1.29	1.72	3.61
Diluted Earning per Share	Rs.	0.83	1.29	1.72	3.61



